Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 87.3%

Neg 87.3% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.